Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1%

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant drop in short interest in February. As of February 27th, there was short interest totaling 56,171 shares, a drop of 15.1% from the February 12th total of 66,140 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 20,697 shares, the short-interest ratio is presently 2.7 days. Based on an average daily trading volume, of 20,697 shares, the short-interest ratio is presently 2.7 days. Approximately 0.2% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on DWTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Dogwood Therapeutics in a research report on Friday, February 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Dogwood Therapeutics presently has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Trading Up 1.7%

DWTX stock opened at $3.06 on Monday. Dogwood Therapeutics has a one year low of $2.60 and a one year high of $9.50. The firm has a 50-day moving average of $3.01 and a two-hundred day moving average of $4.73. The firm has a market capitalization of $98.16 million, a PE ratio of -0.12 and a beta of 1.90.

Institutional Investors Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.